Use of electroacupuncture to accelerate the antidepressant action   of selective serotonin reuptake inhibitors: a single-blind, randomised,   controlled study by Yip, K et al.
Title
Use of electroacupuncture to accelerate the antidepressant
action   of selective serotonin reuptake inhibitors: a single-blind,
randomised,   controlled study
Author(s) Zhang, Z; Ng, R; Man, MSC; Li, J; Wong, W; Wong, HK; Wang, D;Wong, M; Tsang, A; Yip, K; Sze, CW
Citation Hong Kong Medical Journal, 2013, v. 19 n. Suppl. 9, p. 12-16
Issued Date 2013
URL http://hdl.handle.net/10722/195718
Rights Hong Kong Medical Journal. Copyright © Hong Kong Academyof Medicine Press.
HEALTH AND HEALTH SERVICES RESEARCH FUND
12      Hong Kong Med J Vol 19 No 6 Supplement 9 December 2013
Use of electroacupuncture to 
accelerate the antidepressant action 
of selective serotonin reuptake 
inhibitors: a single-blind, randomised, 
controlled study
ZJ Zhang 張樟進
R Ng 吳文建
SC Man 萬帥章
JTY Li 李翠妍
W Wong 黃韻婷
HK Wong 王熙喬
D Wang 王 迪
MT Wong 王萬德
AWK Tsang 曾韋僑
KC Yip 葉嘉池
SCW Sze 施祖榮
Key Messages
1. Patients treated with dense 
cranial electroacupuncture 
stimulation (DCEAS) had a 
significantly greater reduction 
in the 17-item Hamilton Rating 
Scale for Depression scores and 
clinically significant response 
to treatment than those having 
sham acupuncture (19.4% vs. 
8.8%). 
2. Neither sham acupuncture nor 
DCEAS had effects on the 
platelet serotonin system.
3. In the early phase of selective 
serotonin reuptake inhibitor 
treatment for depressed 
patients, DCEAS could be used 
as an additional therapy. 
4. Neurobiological mechanisms 
responsible for DCEAS effects 
warrant further investigation 
using neuroimaging.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) are the mainstay of treatment for 
depressive disorders, but their outcomes are unsatisfactory.1 A large proportion 
of depressed patients cannot obtain a full remission and experience relapse 
and functional impairment. Moreover, the delay in the onset of the action of 
SSRIs prolongs patients’ suffering and exposes them to the risk of suicide. These 
shortcomings have led to the search for alternative strategies to enhance the 
antidepressant efficacy of SSRIs, particularly in the early phase of treatment.2
 Acupuncture is efficacious for various types of depressive disorders, 
particularly in alleviating associated pain, autonomic dysfunction, sleepless, 
and low moods. This is thought to be associated with the fast, direct modulation 
of multiple central neurochemical systems. Adrenergic and serotonergic (5-
HT) mechanisms in the brainstem, as well as neuronal and hypothalamic 
neuroendocrine systems play a pivotal role in the pathophysiology of major 
depression. We therefore hypothesised that electroacupuncture may enhance the 
antidepressant activity of SSRIs in the early phase of treatment. 
 Dense cranial electroacupuncture stimulation (DCEAS) involves electrical 
stimulation of dense acupoints on the forehead mainly innervated by the 
trigeminal nerve. Such acupoints modulates multiple central transmitter systems 
via the trigeminal sensory-brainstem adrenergic and 5-HT neuronal pathways.3 
Pilot studies have shown that DCEAS is effective in improving refractory 
obsessive-compulsive disorder, major depressive disorder (MDD), post-stroke 
depression, and MDD-associated residual insomnia.
 Human platelets are terminally differentiated 5-HT-synthesising cells and are 
similar to 5-HT neurons in terms of synthesis, release, and receptors. Platelets 
have been widely used as a peripheral model for investigation of psychiatric 
disorders associated with the central 5-HT system. We hypothesised that DCEAS 
as additional treatment could produce greater clinical improvement in the early 
phase of SSRI treatment in patients with MDD, and that the antidepressant 
effects of DCEAS may be associated with changes in the platelet 5-HT system.
Methods
This single-blind, randomised, controlled trial was conducted in the Department 
of Psychiatry at the Kowloon Hospital of Hong Kong between May 2009 and 
March 2011. The study protocol was approved by the institutional review board 
of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. 
Based on our recent meta-analysis, a sample size of 35 patients per group could 
provide approximately 80% power to detect an estimated difference in the 17-
item Hamilton Rating Scale for Depression (HAMD-17) score of 3 points, with 
an α set at 0.05 and an estimated standard deviation of 4.5 at the endpoint of 
3-week treatment. 
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 Fluoxetine (FLX) is one of the most prescribed SSRIs 
for major depression worldwide.4 Unmedicated patients in 
both groups received orally administered FLX for 3 weeks. 
The dosage was initiated at 10 mg/day and escalated to an 
optimal dose within 1 week, based on patient response; 
the maximum dose was 40 mg/day. Information about the 
equivalent efficacy of FLX was provided to the patients. 
 
 Of 188 outpatients referred by psychiatrists, 73 were 
eligible and randomly assigned to receive sham acupuncture 
(n=35) and DCEAS (n=38). Informed consent was obtained 
from each patient. Each patient received nine sessions of 
intervention (three sessions per week) during FLX treatment. 
For DCEAS, acupuncture needles were inserted into six 
pairs of forehead acupoints and affixed with adhesive tapes 
to ensure allocation concealment. Electrical stimulation 
at a comfortable level was then delivered for 30 minutes. 
The acupoints were Baihui (Du-20) and Yintang (EX-
HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), 
right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral 
Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral 
Touwei (ST8) [Fig 1]. For sham acupuncture, Streitberger 
non-invasive acupuncture needles were applied and affixed 
in the same way.5 The forehead acupoints were outside the 
visual field of the subjects to ensure blinding. Patients were 
not told about the potential response of both procedures. 
To ensure consistency in acupuncture procedure, the 
principal investigator provided a training workshop about 
the acupuncture protocol. Acupuncture was performed by 
two registered acupuncturists who had practised Chinese 
medicine for over 3 years.
 Outcome was assessed using the HAMD-17, the 
Clinical Global Impression-Severity (CGI-S), and the 
Chinese-version Self-rating Depression Scale (SDS) at 
baseline and at days 3, 7, 14, and 21. Secondary outcome 
measures included the treatment response and remission. 
Safety and tolerability were assessed using the Treatment 
Emergent Symptom Scale, in which adverse events were 
recorded at each visit. All assessments were completed 
by the same rater. A training workshop was provided to 
the rater. Both the patients and the rater were blind to the 
treatment allocation. 
 Two 10-ml blood samples were collected at baseline 
and day 14. Blood samples were also collected from age- 
and gender-matched healthy controls. Platelets and platelet-
poor plasma were separated and the number of platelets 
was counted. The contents of platelet serotonin type 2A 
receptors and serotonin transporter were measured using 
Western blot. The concentrations of 5-HT and its metabolite 
5-hydroxyindoleacetic acid were measured using reverse-
phase high-performance liquid chromatography coupled 
with a fluorescence detector.
 
Results
Of the 73 patients, 63 (86%) completed the 3-week 
assessment. One patient in the sham group who had a history 
of cocaine use and two patients in the DCEAS group who 
did not have post-baseline assessment were excluded from 
analysis (Fig. 2). The proportion of females assigned to the 
sham group was significantly greater (97.1% vs. 69.4%, 
P=0.006, Chi-square test). Other baseline variables were 
similar in both groups (Table 1). Compliance with treatment 
was nearly 95%.
 Changes from baseline in terms of scores of HAMD-
17, CGI-S, and SDS over time revealed linear correlations 
(Table 2). Between-group comparisons revealed that 
DCEAS-treated patients had a significantly greater 
reduction in HAMD-17 scores at day 3 through day 21 
(P≤0.025) and in SDS scores at day 3 (P=0.037) and day 21 
(P=0.004). The response and remission rates were similar in 
both groups. 
 Adverse events occurred in at least 5% of the patients 
in both groups (Table 3). Two patients in the DCEAS group 
discontinued due to intolerance of acupuncture stimulation. 
The credibility rating in the two groups did not differ 
significantly.
 The two groups did not differ significantly at baseline 
and day 14 for all platelet 5-HT parameters (Table 4).
Discussion
The use of DCEAS was effective in augmenting the 
Fig 1. Acupoints used in dense cranial electroacupuncture 
stimulation
Baihui
(Du20)
Sishencong
(EX-HN1) Toulinqi(GB15)
Touwei
(ST8)
Shuaigu
(GB8)
Yintang
(EX-HN3)
Taiyang
(EX-HN5)
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antidepressant efficacy of FLX in patients with moderate 
to severe MDD, as indicated by the significantly greater 
reduction of HAMD-17 and SDS scores. The effect 
was observed as early as day 3 (after the first session of 
treatment). The frequency of adverse events in both groups 
was comparable, and only two DCEAS-treated patients 
discontinued treatment, indicating that it was well tolerated 
and safe. 
 The possibility of a placebo effect of DCEAS was 
also explored. There was no significant difference in the 
credibility of sham acupuncture and DCEAS, suggesting 
that non-inserted needling stimulation was valid and 
acceptable, so it was unlikely that the antidepressant 
Fig 2. Flowchart of screening and patient recruitment
Screened (n=188)
Randomised (n=73)
Assigned to sham acupuncture 
(n=35)
Completed treatment (n=32, 91.4%)
Included in analysis (n=34) Included in analysis (n=36)
Excluded in pre-randomisation (n=115):
 • Refused to participate (n=71)
 • Did not meet the inclusion criteria (n=37)
 • had needle phobia (n=7)
Completed treatment (n=31, 81.6%)
Assigned to dense cranial 
electroacupuncture stimulation (n=38)
Withdrew prematurely (n=3):
 • Lost to follow-up (n=1)
 • Other medical emergency (n=1)
 • Severe headache (n=1)
Withdrew prematurely (n=7):
 • Lost to follow-up (n=2)
 • Other medical emergency (n=3)
 • Intolerance of acupuncture (n=2)
Excluded from analysis due to 
cocaine use found (n=1)
Excluded from analysis due to no post-
baseline assessment (n=2)
Table 1. Baseline characteristics of patients*
Variable Sham acupuncture 
(n=34)
Dense cranial 
electroacupuncture 
stimulation (n=36)
P value 
(t or χ2 test)
Female 33 (97.1) 25 (69.4) 0.006
Age (years) 48.2±9.8 46.3±9.9 0.414
Duration of major depressive disorder (years) 7.3±7.1 7.9±8.0 0.744
No. of previous depressive episodes 3.6±4.4 4.9±6.1 0.332
Patients with first-onset major depressive disorder 3 (8.8) 2 (5.5) 0.669
Patients with previous psychiatric admission 8 (23.5) 7 (19.4) 0.901
Patients with family members having mental illnesses 9 (26.5) 13 (36.1) 0.800
Patients with previous acupuncture treatment 22 (64.7) 24 (66.7) 0.937
Patients receiving psychotropic medications at study entry (not exceeding 1 week) 6 (17.6) 7 (19.4) 0.909
Selective serotonin re-uptake inhibitors 3 3
Serotonin-norepinephrine reuptake inhibitors 1 1
Mood stabilisers 1 1
Benzodiazepines 2 2
Baseline 17-item Hamilton Rating Scale for Depression score 23.1±3.6 23.9±3.8 0.321
Baseline Clinical Global Impression-Severity 4.3±0.5 4.4±0.5 0.760
Baseline Self-rating Depression Scale score 40.6±14.5 41.9±14.0 0.704
* Data are presented as no. (%) or mean±SD
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Table 2. Changes in depression scores from baseline
Variables Mean (95% CI) change in score from baseline P value (linear 
mixed effects 
model)Sham acupuncture (n=34) 
Dense cranial 
electroacupuncture 
stimulation (n=36) 
Between-group 
difference
17-item Hamilton Rating Scale for Depression
Day 3 -3.71 (-4.34 to -3.06) -5.97 (-6.71 to -5.23) 2.27 (1.29 to 3.25) 0.000
Day 7 -5.82 (-6.46 to -5.18) -6.97 (-7.71 to -6.23) 1.15 (0.17 to 2.13) 0.025
Day 14 -6.41 (-7.05 to -5.77) -8.44 (-9.18 to -7.70) 2.03 (1.05 to 3.01) 0.000
Day 21 -6.27 (-6.90 to -5.62) -8.66 (-9.39 to -7.91) 2.39 (1.41 to 3.37) 0.000
Clinical Global Impression-Severity
Day 3 -0.32 (-0.42 to -0.22) -0.44 (-0.54 to -0.34) 0.12 (-0.03 to 0.27) 0.116
Day 7 -0.65 (-0.75 to -0.55) -0.53 (-0.63 to -0.43) 0.12 (-0.03 to 0.27) 0.116
Day 14 -0.71 (-0.81 to -0.61) -0.71 (-0.81 to -0.61) 0.00 (-0.15 to 0.15) 1.000
Day 21 -0.74 (-0.84 to -0.64) -0.74 (-0.84 to -0.64) 0.00 (-0.15 to 0.15) 1.000
Self-rating Depression Scale
Day 3 -6.44 (-8.48 to -4.40) -9.76 (-12.03 to -7.49) 3.32 (0.26 to 6.38) 0.037
Day 7 -8.82 (-10.86 to -6.78) -9.12 (-11.39 to -6.85) 0.30 (-2.76 to 3.36) 0.851
Day 14 -11.74 (-13.78 to -9.70) -12.38 (-14.65 to -10.11) 0.64 (-2.42 to 3.70) 0.679
Day 21 -8.38 (-10.42 to -6.34) -13.06 (-15.33 to -10.79) 4.68 (1.62 to 7.74) 0.004
Table 3. Adverse events during treatment
Adverse event No. (%) of patients χ2 P value
Sham acupuncture (n=34) Dense cranial electroacupuncture 
stimulation (n=36)
Dizziness 15 (44.1) 11 (30.6) 0.858 0.354
Tiredness 10 (29.4) 15 (41.7) 0.672 0.412
Nausea 10 (29.4) 10 (27.8) 0.013 0.910
Excessive sweating 9 (26.5) 6 (16.7) 1.403 0.236
Headache 8 (23.5) 10 (27.8) 0.018 0.894
Transient tachycardia 8 (23.5) 9 (25.0) 0.018 0.892
Insomnia 7 (20.6) 9 (25.0) 0.024 0.877
Discomfort during needling sensation 7 (20.6) 14 (38.9) 1.985 0.159
Vomiting 4 (11.8) 3 (8.3) - 0.706*
Unsteadiness 2 (5.9) 6 (16.7) - 0.266*
Somnolence 2 (5.9) 6 (16.7) - 0.266*
* Fisher Exact test was used
Table 4. The effects of dense cranial electroacupuncture stimulation on platelet 5-HT parameters
* vs. healthy controls, P<0.01, one-way analysis of variance
benefits of DCEAS were derived from placebo effects. 
 There were several limitations in the present study. 
First, most subjects were females. There may be gender- 
and ethnic-differences in acceptance and credibility of 
acupuncture, suggesting a form of demographic bias. 
Single-blind treatment allocation might lead to effects 
mediated by the non-blind acupuncturists. Second, DCEAS 
only achieved a clinically meaningful (but not significant) 
difference in terms of the response rate (DCEAS: 19.4% 
vs. sham: 8.8%). This may be related to the relatively 
short-term (3-week) treatment. Long-term studies of 
antidepressant efficacy of DCEAS are warranted. Finally, 
no significant changes in platelet 5-HT parameters (baseline 
Variable Mean±SD value
Healthy controls 
(n=22)
Sham acupuncture (n=34) Dense cranial electroacupuncture 
stimulation (n=36)
Baseline Week 2 Baseline Week 2
Platelet
Serotonin type 2A receptors 1.3±0.2 2.6±1.5* 2.5±1.5 2.6±1.5* 2.5±1.5
Serotonin transporter 1.6±0.2 2.3±1.5 2.0±1.5 2.2±1.8 2.1±1.8
5-HT (ng/109) 527.2±111.1 81.8±92.8* 81.6±91.8 84.3±62.2* 87.0±74.2
5-hydroxyindoleacetic acid (ng/109) 632.9±214.6 192.3±129.0* 231.7±196.1 215.2±149.5* 249.6±203.3
Turnover 0.9±0.3 0.7±1.2 0.7±0.7 0.6±0.6 0.6±0.6
Platelet-poor plasma
5-HT (ng/ml) 9.3±1.6 4.8±1.5* 5.3±1.2 5.5±2.3* 5.4±2.4
5-hydroxyindoleacetic acid (ng/ml) 10.4±2.3 6.7±2.9* 7.5±3.6 7.0±3.0* 7.1±3.3
Turnover 1.0±0.3 0.8±0.5 0.8±0.4 0.9±0.4 0.9±0.5
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to post-treatment) were noted in DCEAS-treated patients, 
suggesting that DCEAS may have minimal effects on 
platelet 5-HT systems. Evaluation of DCEAS effects on the 
brain 5-HT neuronal system may provide insight into central 
mechanisms responsible for the antidepressant effects of 
DCEAS. Several baseline 5-HT parameters of depressed 
patients differed significantly from those of healthy 
controls, and correlated significantly with the severity of 
depression symptoms. The platelet 5-HT indices seem to be 
potential biomarkers, reflecting the clinical status of major 
depression, although they are not directly involved in the 
physiopathology of major depression. 
Implications
As patients with moderate and severe major depression 
have a higher risk of suicide and symptom worsening in the 
early phase of SSRI treatment, DCEAS can be an additional 
therapy. Neurobiological mechanisms responsible for 
DCEAS effects may warrant further investigation using 
neuroimaging approaches.
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